Toggle navigation
Home
Search
Services
Blog
Contact
About
Clinical Trial of an Improved Melanoma Vaccine
Bystryn, Jean-Claude
New York University, New York, NY, United States
Search 38 grants from Jean-Claude Bystryn
Search grants from New York University
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Fred Hutchinson Cancer Research Center
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Intestinal allograft tolerance in large animals
Runachay: Information and Communication Technologies for Global Health Research
Discriminative Effects of Benzodiazepine Withdrawal
In vivo Gene Correction of Keratin 14 Gene in EBS Mouse
Educational and Research Infrastructure Development in Microelectromechanical Systems
Recently added grants:
Voltage-dependent ion channels controlling firing patterns of central neurons
Development and Function of 5HT3aR-Expressing Cortical GABAergic Interneurons
Developmental Patterning of the Anterior Neural Plate in a Simple Chordate
ER Ca2+ store mediated white matter injury
Administrative Core
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA066669-01A1
Application #
2110107
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1996-03-01
Project End
1998-02-28
Budget Start
1996-03-01
Budget End
1997-02-28
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
New York University
Department
Dermatology
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Related projects
NIH 1997
R21 CA
Clinical Trial of an Improved Melanoma Vaccine
Bystryn, Jean-Claude / New York University
NIH 1996
R21 CA
Clinical Trial of an Improved Melanoma Vaccine
Bystryn, Jean-Claude / New York University
Publications
Reynolds, S R; Celis, E; Sette, A et al.
(1998)
HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
J Immunol 161:6970-6
Comments
Be the first to comment on Jean-Claude Bystryn's grant